ArticleMolecular imaging and biology2026
Cross-Species Quantitative Benchmarking of SSTR2 Radioligands in Fresh-Frozen Brain Sections: An Adaptable Framework for Radiopharmaceutical Development.
Article in Molecular imaging and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleSomatostatin receptor subtype 2 (SSTR2) is a G-protein coupled receptor overexpressed in multiple cancers, including neuroendocrine tumors, small cell lung cancer, and hepatocellular carcinoma. Clinical validation of SSTR2-targeted radioligand therapy (Lutathera™) has driven development of next-generation ligands. Progress in next-generation SSTR2 ligand development is strengthened by quantitative platforms that preserve native receptor context and enable quantitative, cross-species binding data to drive translation and radiotherapeutic advancement.
methodsFresh-frozen tissue sections from mouse, rat, cynomolgus monkey and human brain were assessed for SSTR2 binding using the high affinity antagonist [
resultsAcross all species, [
conclusionsThis native-tissue platform provides efficient, translatable, reproducible and absolute quantification of SSTR2 ligand binding without tissue standards, supporting early selection of chemotypes, radiometals, and species-bridging expectations before in vivo studies.
Indexed as
Identifiers
42423881What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.